ReAlta Secures $40M for HIE Therapy Advancement
April 14, 2026, 3:35 am
Location: United States
Employees: 11-50
Founded date: 2018
Total raised: $74M
ReAlta Life Sciences secured $40M, pushing total funding over $150M. This capital fuels the advancement of pegtarazimod, its lead drug for Hypoxic Ischemic Encephalopathy (HIE). HIE devastates newborns; current options are limited. Pegtarazimod, a dual-targeting peptide, aims to revolutionize HIE treatment. It holds Orphan Drug and Fast Track designations. The funds will propel its Phase 2 STAR trial and critical FDA milestones. This innovative therapy seeks to address inflammation and brain injury, offering new hope for affected infants. ReAlta strives to redefine HIE care with this novel approach.
A pivotal financial boost arrived for ReAlta Life Sciences. The Norfolk, VA-based biopharmaceutical company successfully closed an oversubscribed $40 million funding round. This significant infusion of capital elevates ReAlta’s total financing to more than $150 million since its inception. The investment directly targets the development of pegtarazimod, a groundbreaking therapy for Hypoxic Ischemic Encephalopathy (HIE).
These newly acquired funds are earmarked for critical strategic objectives. The company will aggressively advance pegtarazimod (RLS-0071) through its ongoing clinical and regulatory pathway. Key milestones include the completion of the Phase 2 STAR trial. This trial is vital. A subsequent top-line data readout will provide crucial efficacy and safety insights. The process culminates in an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). These steps are essential for potential drug approval.
Pegtarazimod stands as ReAlta’s lead therapeutic candidate. It offers a fundamentally new approach to HIE treatment. This innovative drug is a first-in-class, dual-targeting peptide. Its mechanism of action directly addresses the core inflammatory processes. These processes drive brain injury in HIE patients. The therapy works by selectively inhibiting complement activation. It also blocks neutrophil-mediated inflammation. Both pathways are critical contributors to neurological damage. This occurs following oxygen deprivation at birth. By targeting these upstream drivers, pegtarazimod aims to disrupt the inflammatory cascade early. It seeks to rebalance the body’s destructive response. This strategy prevents further tissue damage, offering neuroprotection.
The urgency for effective HIE treatments cannot be overstated. HIE is a devastating condition. It affects thousands of newborns each year across the United States and globally. Infants suffer severe brain injury due to oxygen deprivation. This often leads to lifelong neurological impairments. Cerebral palsy, developmental delays, and cognitive deficits are common consequences. The emotional and financial toll on families is immense. Current medical interventions are severely limited. Therapeutic hypothermia is the standard of care. It provides only modest benefits. No approved drug therapies currently exist to specifically treat HIE. This creates an enormous unmet medical need. ReAlta’s approach could bridge this critical gap.
Regulatory bodies have recognized pegtarazimod’s profound potential. The FDA has granted the therapy two significant designations. It received both Orphan Drug and Fast Track status. The European Medicines Agency (EMA) also designated it as an Orphan Drug. These designations accelerate the development process. Fast Track status allows for expedited review. Orphan Drug status encourages therapies for rare diseases. These recognitions underscore the severe lack of current treatment options. They also highlight the anticipated impact of pegtarazimod on newborn brain injury.
The Phase 2 STAR trial is a cornerstone of pegtarazimod’s clinical development. This important study is actively enrolling patients. It operates across 13 leading neonatal intensive care units (NICUs) throughout the United States. The trial evaluates pegtarazimod in newborns suffering from moderate to severe HIE. All participating infants are also undergoing therapeutic hypothermia. Clinical data from this trial will be pivotal. It will inform future development stages. It will assess the drug’s ability to improve neurological outcomes.
ReAlta Life Sciences remains committed to redefining treatment paradigms. The company focuses on severe, historically untreatable inflammation-driven diseases. Its peptide platform delivers precise, targeted interventions. Leadership emphasizes a disciplined and focused strategy. They aim to efficiently deploy capital. The goal extends beyond incremental improvements in HIE care. The vision is to establish a fundamentally new category of medicine. This could transform how doctors manage and treat newborn brain injury.
This latest financing round signifies robust investor confidence. It validates the scientific rigor behind pegtarazimod. It also reflects the urgent human need the therapy addresses. ReAlta Life Sciences is well-positioned. It can now execute key value-inflection points. The company anticipates delivering meaningful clinical and strategic milestones. This innovative biopharmaceutical firm is striving to realize a future. In this future, infants affected by HIE have a genuine therapeutic option. This could significantly improve their long-term health and development. The journey toward a new standard of care for HIE continues with renewed momentum.
A pivotal financial boost arrived for ReAlta Life Sciences. The Norfolk, VA-based biopharmaceutical company successfully closed an oversubscribed $40 million funding round. This significant infusion of capital elevates ReAlta’s total financing to more than $150 million since its inception. The investment directly targets the development of pegtarazimod, a groundbreaking therapy for Hypoxic Ischemic Encephalopathy (HIE).
These newly acquired funds are earmarked for critical strategic objectives. The company will aggressively advance pegtarazimod (RLS-0071) through its ongoing clinical and regulatory pathway. Key milestones include the completion of the Phase 2 STAR trial. This trial is vital. A subsequent top-line data readout will provide crucial efficacy and safety insights. The process culminates in an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). These steps are essential for potential drug approval.
Pegtarazimod stands as ReAlta’s lead therapeutic candidate. It offers a fundamentally new approach to HIE treatment. This innovative drug is a first-in-class, dual-targeting peptide. Its mechanism of action directly addresses the core inflammatory processes. These processes drive brain injury in HIE patients. The therapy works by selectively inhibiting complement activation. It also blocks neutrophil-mediated inflammation. Both pathways are critical contributors to neurological damage. This occurs following oxygen deprivation at birth. By targeting these upstream drivers, pegtarazimod aims to disrupt the inflammatory cascade early. It seeks to rebalance the body’s destructive response. This strategy prevents further tissue damage, offering neuroprotection.
The urgency for effective HIE treatments cannot be overstated. HIE is a devastating condition. It affects thousands of newborns each year across the United States and globally. Infants suffer severe brain injury due to oxygen deprivation. This often leads to lifelong neurological impairments. Cerebral palsy, developmental delays, and cognitive deficits are common consequences. The emotional and financial toll on families is immense. Current medical interventions are severely limited. Therapeutic hypothermia is the standard of care. It provides only modest benefits. No approved drug therapies currently exist to specifically treat HIE. This creates an enormous unmet medical need. ReAlta’s approach could bridge this critical gap.
Regulatory bodies have recognized pegtarazimod’s profound potential. The FDA has granted the therapy two significant designations. It received both Orphan Drug and Fast Track status. The European Medicines Agency (EMA) also designated it as an Orphan Drug. These designations accelerate the development process. Fast Track status allows for expedited review. Orphan Drug status encourages therapies for rare diseases. These recognitions underscore the severe lack of current treatment options. They also highlight the anticipated impact of pegtarazimod on newborn brain injury.
The Phase 2 STAR trial is a cornerstone of pegtarazimod’s clinical development. This important study is actively enrolling patients. It operates across 13 leading neonatal intensive care units (NICUs) throughout the United States. The trial evaluates pegtarazimod in newborns suffering from moderate to severe HIE. All participating infants are also undergoing therapeutic hypothermia. Clinical data from this trial will be pivotal. It will inform future development stages. It will assess the drug’s ability to improve neurological outcomes.
ReAlta Life Sciences remains committed to redefining treatment paradigms. The company focuses on severe, historically untreatable inflammation-driven diseases. Its peptide platform delivers precise, targeted interventions. Leadership emphasizes a disciplined and focused strategy. They aim to efficiently deploy capital. The goal extends beyond incremental improvements in HIE care. The vision is to establish a fundamentally new category of medicine. This could transform how doctors manage and treat newborn brain injury.
This latest financing round signifies robust investor confidence. It validates the scientific rigor behind pegtarazimod. It also reflects the urgent human need the therapy addresses. ReAlta Life Sciences is well-positioned. It can now execute key value-inflection points. The company anticipates delivering meaningful clinical and strategic milestones. This innovative biopharmaceutical firm is striving to realize a future. In this future, infants affected by HIE have a genuine therapeutic option. This could significantly improve their long-term health and development. The journey toward a new standard of care for HIE continues with renewed momentum.